Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Shanghai Stock Exchange 688621.SS

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 4.29

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Price to Sales Ratio (P/S) is 4.29 on January 14, 2025, a -48.56% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Beijing Sun-Novo Pharmaceutical Research Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 8.47 on January 18, 2024, which is 97.60% above the current Price to Sales Ratio (P/S).
  • Beijing Sun-Novo Pharmaceutical Research Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 3.53 on September 23, 2024, which is -17.53% below the current Price to Sales Ratio (P/S).
  • Beijing Sun-Novo Pharmaceutical Research Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 5.57.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Shanghai Stock Exchange: 688621.SS

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

CEO Mr. Yujing Liu
IPO Date June 21, 2021
Location China
Headquarters Building 7
Employees 1,370
Sector Health Care
Industries
Description

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China. The company offers small molecule chemical generic drugs; peptide products; and drugs for indications, such as impetigo, acne, renal anemia, chronic kidney disease dialysis patient hyper parathyroid hormone, analgesia, and other symptoms. It also provides packaging material compatibility test, impurity research, extract research, migration research, safety evaluation, and other research services; consistency evaluation services; clinical research services; registration consulting and agency services; and range of pharmacokinetics-pharmacodynamics and GLP bioanalysis services, including pharmacokinetic bioanalysis, immunogenic biology analysis, pharmacodynamics, and biomarker bioanalysis services. The company was founded in 2009 and is based in Beijing, China.

Similar companies

300122.SZ

Chongqing Zhifei Biological Products Co., Ltd.

USD 3.45

3.36%

603456.SS

Zhejiang Jiuzhou Pharmaceutical Co., Ltd

USD 1.78

2.51%

688363.SS

Bloomage BioTechnology Corporation Limited

USD 6.87

3.48%

002759.SZ

Tonze New Energy Technology Co.,Ltd.

USD 1.09

4.04%

StockViz Staff

January 16, 2025

Any question? Send us an email